• Knightscope’s ASRs have completed over one million field hours and are continuing to improve over time based on field experience
• Knightscope designs, engineers, and builds its ASRs in Silicon Valley, continuing to create American jobs in an economy severely impacted by the pandemic
• The company is committed to changing the way public safety and protection are delivered nationwide
• By joining the $39 billion self-storage industry, Knightscope is targeting to become a prominent security provider in the sector, translating into further opportunities for growth

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous robots focused on enhancing U.S. security operations, is committed to helping create peace and maintaining public safety nationwide via the superior technology it develops and deploys. Combining self-driving technology, robotics and artificial intelligence, Knightscope’s Autonomous Security Robots (“ASRs”) provide 24/7/365 security and are currently patrolling five time zones across the United States, assisting in the creation of safer public and private spaces. The company’s ASRs are a means of physical deterrence, patrolling sites autonomously and providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The collected data is available round the clock through the company’s Knightscope Security Operations Center (KSOC), an intuitive interface that also features 360-degree eye-level HD video streaming, facial recognition, people detection, thermal anomaly detection, automatic license plate recognition, and automatic signal detection. In a recent video presentation titled “Knightscope: Peace Through Superior Technology,” CEO William Santana Li explained how Knightscope’s ASRs are changing the way protection is delivered across the United States (https://ibn.fm/dg15A). It is estimated that there are two million police officers and security personnel across the United States for more than 300 million people across the 50 states. Knightscope’s ASRs are helping to bridge the gap, covering more ground with round-the-clock coverage. In addition to patrolling and peacekeeping, the ASRs have already helped law enforcement and security with the arrests of suspects in crimes that range from armed robbery to hit-and-run accidents. More information about the work Knightscope is doing to fight crime is available at www.Knightscope.com/crime. The current ASR product offering from Knightscope currently includes a K1 stationary unit, a K3 indoor machine, and the K5 outdoor machine. Since the K5 outdoor machine’s deployment, the City of Huntington Park Police Department has noted significant changes in their calls for service (down 10%), crime reports (down 46%), arrests (up 27%), and citations (down 68%). The data was compiled from June to December 2018, before deployment, and compared to June to December 2019, after deployment. Since the company’s creation in 2013, several milestones have already been achieved, including:

• Establishing a 15,000-square-foot facility in Mountain View, California, where Knightscope designs, engineers, and builds their proprietary technology;
• Completing more than one million hours in the field, securing contracts across five United States’ time zones; and
• Continuing to hire and navigate the global pandemic without interruptions, despite the current economic and societal disruptions.

Furthering its position in the industry, Knightscope recently signed an agreement with a Southern California storage facility to utilize the company’s ASR technology. Storage units are particularly susceptible to theft and vandalization. Entry into this $39 billion a year industry offers Knightscope tremendous potential for growth (https://ibn.fm/9S9BC). The long-term vision of Knightscope is to keep an eye on the greater good. The company’s mission is to make the United States of America the safest nation, supporting millions of law enforcement and security personnel across the country. For more information, visit the company’s website at www.Knightscope.com.    Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button in the lower right corner (it is not a bot) for direct contact with CEO.  NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• BRSF announce partnership with Dalmore Group
• New product launch presents solution for growing need for rapid EEG testing due to COVID-19 pandemic
• Brain Scientific shose to extend proposed Reg A+ offering to attract additional investors

Brain Scientific (BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, has announced a partnership with the Dalmore Group in a recent press release (https://ibn.fm/clcDx). “We are delighted to get the Dalmore Group on board and to be able to offer our stock to a much wider pool of investors,” said Brain Scientific chairman Boris Goldstein. “Our partners are experienced with Regulation A+ offerings and are licensed in all 50 states.” The Dalmore Group is a member of FINRA and SIPC with an active presence in the Regulation A+ equity funding space. As one of the most active broker-dealers in the world, the company has served as broker-dealer on more than 50 RegA+ offerings in the past 12 months alone. In 2019 the Dalmore Group raised over $1 billion of capital. The majority of Dalmore Group’s clients come by referral from securities attorneys and industry participants. BRSF is looking to the Dalmore Group for its expert strategic advice and innovative solutions. The Dalmore Group prides itself on understanding a client’s critical business processes and financial goals in order to provide the most comprehensive services possible. Brain Scientific recently launched the next-gen, 19-channel NeuroCap(TM) device. This is a hospitable-grade disposable EEG headset that presents a solution for the growing need for rapid EEG testing due to the COVID-19 pandemic. Through the use of a special adapter, the NeuroCap is compatible with any other amplifiers of EEG signals. Two of the biggest challenges of administering EEGs is the need to measure a patient’s head and the time needed to place the electrodes accurately. This required a specialized neurological technician. The pre-gelled fixed electrode locations, in accordance with the International 10-20 System, allow the NeuroCap to be administered by any healthcare worker making it more accessible to a larger group of patients. The ease of use opens the device up for application in hospitals, clinics and rural areas where medical resources may be limited. Also, the global pandemic is still raging, and new studies show more than 80% of hospitalized COVID-19 patients have neurological symptoms, which could require EEG testing (https://ibn.fm/qRf8w). “With our recent product development and new product launches,” said Goldstein, “we feel the need to extend the proposed Regulation A+ Offering to attract additional investors, which we believe we can better accomplish by working with Dalmore.” For more information, visit the company’s website at www.BrainScientific.com. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Globally it is estimated that 70,000 people suffer from CF, with half the population in the United States
• The global CF therapeutics market size was valued at $4.62 billion in 2018 and is expected to reach an estimated $9.3 billion by 2026
• AzurRx BioPharma’s MS1819, currently undergoing clinical trials, is a promising therapy for severe exocrine pancreatic insufficiency in patients with cystic fibrosis

While still a relatively rare genetic disease, cystic fibrosis (“CF”) remains a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening illnesses. This is why the need for innovative and effective therapies for the treatment of CF-associated ailments, such as AzurRx BioPharma’s (NASDAQ: AZRX) drug candidate for exocrine pancreatic insufficiency, is constantly growing. According to Allied Market Research, the demand for effective treatment options is driving a global expansion of the CF therapeutics market. Further driven by the availability of personalized drug therapy and molecular prosthetics, the global CF therapeutics market is expected to reach $9.3 billion by 2026, from $4.62 billion in 2018 (https://ibn.fm/E8kIz). Cystic fibrosis is a progressive, genetic disease characterized by persistent lung infections and limited breathing ability over time as well as significant digestive problems. It is caused by a mutation of the cystic fibrosis transmembrane conductance regulator (“CFTR”) gene making it unable to transport salts across cell membranes, resulting in the buildup of thick and sticky mucus in different organs and tissues. In the lungs, the mucus clogs the airways and traps germs, which leads to infections, respiratory failure, inflammation, and other complications. The pancreas is also affected by the buildup of mucus, which prevents the release of digestive enzymes. These digestive enzymes are key to absorbing food and nutrients, often leading to malnutrition and poor growth (https://ibn.fm/ucQP4). Many patients with CF have a weak immune system and are also at a higher risk of developing other severe health conditions, such as hypersplenism, diabetes, cirrhosis, osteoporosis and arthritis. Globally, it is estimated that 70,000 people suffer from cystic fibrosis, but the incidence of the disease varies significantly across the globe, as prenatal and newborn screening for CF is not standard practice. The U.S. has one of the highest incidence rates with about 35,000 diagnosed cases, according to the Centers for Disease Control (https://ibn.fm/YBzVq). A World Health Organization report indicates that the incidence of CF in the U.S. is one in every 3,500 births and slightly higher in the European Union, where one in 2,000-3,000 newborns are affected (https://ibn.fm/DEFzu). While the condition is largely underdiagnosed in Africa and Asia, a recent study out of India showed that the prevalence of cystic fibrosis could be higher than previously believed. Research conducted by Sir Ganga Ram hospital in Rajendra Nagar, Delhi, and published in the BMC Medical Genetics of London, indicated that one in 2,000 newborns in the populous Asian nation may be at risk of being born with CF, after finding a high carrier frequency of 4.5% in male and female subjects (https://ibn.fm/fCIZ4). AzurRx’s MS1819 Showing Promising Results Technological advances have greatly increased the lifespan for those suffering from CF, especially since the 1950s when children with CF rarely made it to elementary school age (https://ibn.fm/5m5XR). The median age of survival for a CF patient is now around 47 years, with many patients living into their 60s (https://ibn.fm/66lO7). Due to the efforts of companies such as AzurRx BioPharma, the lifespan and quality of life of CF patients could be further improved. AzurRx’s lead product is MS1819, a recombinant lipase that could potentially change the treatment of exocrine pancreatic insufficiency (“EPI”) in CF and chronic pancreatitis (“CP”) patients. The company is currently undergoing Phase 2 trials and pursuing approval through parallel monotherapy and combination therapy pathways. The two current clinical trials for MS1819 in CF patients are a Phase 2b Option 2 monotherapy trial and a Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (“PERT”), the current standard of care. Preliminary results from the combination trial have shown clinically meaningful improvements in subjects, with no adverse safety events. The company believes that due to its safety and efficacy, MS1819 has the potential to improve the quality of life and help achieve healthier nutrition for many patients suffering from severe EPI. AzurRx is scheduled to complete treatment of all patients and announce top line data from both clinical studies in 2021. For additional information, visit www.AzurRx.com or contact the following: AzurRx BioPharma, Inc. Martin Krusin Vice President for Corporate Development Phone: (646) 699-7855 info@azurrx.com NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

• Technical report supports recent positive feasibility study announcement
• Study projects average annual metal production of 136,000 tonnes of copper, 231,000 ounces of gold and million-plus ounces of silver
• Josemaria one of world’s very few readily developable copper-gold projects

Josemaria Resources (TSX: JOSE) (OTC: JOSMF) has filed a key technical report to support its recent positive feasibility study announcement. The report, which was prepared under National Instrument 43-101 Standards for Disclosure for Mineral Projects, is in regard to the company’s wholly owned Josemaria Copper-Gold Project, located in San Juan Province in Argentina. Last month Josemaria Resources announced the positive results of a feasibility study focused on its Argentine property. The study reported a robust, rapid pay-back, low-risk project with an open-pit operation feeding a conventional process plant at 152,000 tonnes a day; the mine life was estimated to last 19 years. The study projected an average annual metal production of 136,000 tonnes of copper, 231,000 ounces of gold and more than a million 1,164,000 ounces of silver. “We are extremely pleased with the results of the Feasibility Study at Josemaria, which indicates that this is one of the very few readily developable copper-gold projects in the world today,” said Josemaria Resources president and CEO Adam Lundin. “This study has materially de-risked the project and forecasts an attractive economic outcome which is comparable with other large-scale copper/gold projects already being developed or in production today. We believe that Josemaria is perfectly positioned to commence production by mid-decade, meeting rising copper demand from a rapidly electrifying global economy. I believe the study results will allow us to unlock various financing opportunities as we move toward construction.” The study was prepared by a team of engineering and consulting service providers led by Fluor Canada Ltd. with key sections prepared by SRK Consulting (Canada) Inc. and Knight Piésold Ltd. The study was conducted in accordance with the disclosure standards of National Instrument 43-101. The feasibility report comes at an ideal time for JOSE. In 2019, the global smart mining market totaled approximately $6.8 billion; current trends indicate it will more than triple that by 2025, reaching approximately $20.31 billion. That increase, experts observe, will be driven by technological advancements within the sector. Another positive indicator for the Josemaria project is the steady growth in demand for both copper and gold. The global copper market is expected to reach $222.1 billion by the end of 2026, while demand for gold is also expected to rise as economic uncertainty increases globally. Josemaria Resources is a Canadian natural resources company based in Vancouver, British Columbia. The company’s current focus is on advancing the development of its wholly owned Josemaria copper-gold mining project. Josemaria Resources is part of the Lundin Group of companies, a conglomerate of 13 business entities operating in the mining, oil and gas and renewables sectors around the world. For more information on Josemaria Resources, visit the company’s website at www.JosemariaResources.com. NOTE TO INVESTORS: The latest news and updates relating to JOSMF are available in the company’s newsroom at https://ibn.fm/JOSMF

• Life sciences technology innovator Pressure BioSciences (OTCQB: PBIO) has increased its IP stable to 26 patents worldwide with the announcement of its first U.S. patent for its revolutionary Ultra Shear Technology(TM) (“UST”) Platform
• The patent (US 10,823,159) – entitled “System for High Pressure, High Shear Processing of Fluids” – will be the framework of the company’s new instrument line (the BaroShear K45 Nanoemulsification System) to be commercially released in mid-2021
• UST is expected to revolutionize the processing of immiscible liquids into high quality, highly profitable nanoemulsions
• Nanoemulsions are highly sought after in a variety of industries because of their ability to improve stability, appearance, taste, and/or water solubility of retail products (e.g., food, beverages, cosmetics) as well as for the delivery and bioavailability of biopharmaceutical drugs and vaccines
• The legal cannabidiol (“CBD”) industry has been particularly attractive to the company because of its nascent and enormous popularity, leading to projections from multiple sources that it will surge to a $47 billion market by 2025
• Pressure BioSciences expects to deliver on the preorder of its first dozen BaroShear K45 Systems during the first half of next year, which is expected to generate additional revenue for the company of about $3 million, and that is just for the first half of 2021

Pressure BioSciences (OTCQB: PBIO) recently announced the issuance of the first U.S. patent for its  innovative Ultra Shear Technology (UST) platform  that utilizes ultra high pressure and intense shearing forces to make unique, high-quality nanoemulsions that have enormous use in a wide variety of industries. The announcement brings PBI’s IP patent portfolio up to 26 worldwide and should move the company rapidly towards significantly increased revenue and profitability. The patent for the company’s trademarked Ultra Shear Technology (“UST”) platform entitled “System for High Pressure, High Shear Processing of Fluids” is the first long-term patent (20-year) for UST in the world, and takes Pressure BioSciences another step closer toward its mid-2021 planned commercial release of the BaroShear K45 System, which will be the company’s first UST-based processing system to reach the market (https://ibn.fm/ozzPZ). The UST platform was created to revolutionize the process of mixing liquids that normally do not mix, such as oil and water, but without the need for high quantities of chemicals that are all too common in today’s nanoemulsions. The chemically emulsified mixtures of these liquids currently have wide use in everyday products, such as foods, pharmaceutical drugs and nutraceuticals, cosmetics, industrial lubricants and most recently cannabis oil extracts that are becoming increasingly popular with legalization.  PBI’s UST processed nanoemulsions are expected to exceed the quality of today’s chemically-produced nanoemulsions, while decreasing the cost of manufacture and minimizing the need for large amounts of added chemicals. Nano particles offer a large surface area in relation to their volume due to their small size, which provides them with special chemical, physical and biological properties in contrast to bulk matter at normal scale (https://ibn.fm/sJn1N). While nano particles are currently used in high-quality items like scratch-proof glasses and transparent sunscreens, their medical applications are perhaps of greatest interest. Drug makers look to nano emulsions as a means of transporting medicines to specifically targeted disease cells, such as cancers, reducing damage to nearby healthy ones. Lipid-based nano particles (“LNP”) are increasingly sought after as vaccine carriers for preventative medical purposes as well.  PBI’s UST nanoemulsification platform offers the potential to quickly and successfully compete in these existing areas, because of its many advantages over current processes. The hemp-derived cannabidiol (“CBD”) market’s pursuit of efficient nanoemulsification for superior delivery, absorption, and bioavailability of its oil-based nutraceuticals is also a potentially very lucrative market because changing perspectives toward cannabis worldwide have created a booming nascent industry. Cannabis market research firm BDS Analytics CEO Roy Bingham predicts legal CBD will become a $47 billion market by 2025 (https://ibn.fm/xZllS). “Nanoemulsions have long been shown to exhibit improved absorption, higher bioavailability, and greater stability, while often requiring lower levels of emulsifiers than macro/micro emulsion products,” Senior Vice President of Engineering Dr. Edmund Y. Ting stated in the company announcement. “Because of these significant advantages, nanoemulsions are currently the focus of numerous research efforts worldwide. However, cost-effective scale-up of high quality nanoemulsion processing at a commercial level continues to be quite challenging. Importantly, we believe that PBI’s innovative and now patented UST platform can provide the key to commercial success for nanoemulsion products.” The company has received pre-orders for 12 BaroShear K45 systems, which it plans to deliver during the first half of 2021 for up to $3 million in additional revenue (https://ibn.fm/TgON9). Pressure BioSciences also is in talks with academic organizations and government agencies that have expressed interest in the UST platform for other product and research possibilities, such as an alternative for processing fresh milk, juices, and other dairy products into a long-term stable, room temperature, tasty products. For more information, visit the company’s website at www.PressureBioSciences.com. NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• HempFusion Wellness, Inc. is a health and wellness company developing the power of whole-food hemp nutrition through more than 40 products currently on store shelves
• The company is focused on industry safety and quality standards through regulatory compliance, and is currently participating in a real world consumer study to establish the safety of daily cannabidiol (“CBD”) use in regard to liver function
• HempFusion has filed a preliminary prospectus for a planned initial public offering of its stock in Canada and a listing on the Toronto Stock Exchange
• Despite a reduction in hemp farm acreage this year following last year’s glut, market watchers anticipate the industrial hemp market is expected to reach $22 billion by 2022

The U.S. election this month demonstrated the lasting potential of the market for cannabis-derived products when five states joined the march toward legalizing marijuana for recreational or medicinal uses (https://ibn.fm/T6k3q). Despite a variety of challenges that plagued the nascent hemp industry in 2019 as well as the contentious societal debates over the COVID-19 pandemic’s impact on everyday life and the choices for president, cannabis’ hemp and marijuana offshoots seem to have transcended the upheaval that has defined 2020. Denver-based HempFusion Wellness has continued to build its own movement toward market success in the cannabis wellness industry, developing 46 products that are currently on shelves while establishing the second-largest cash position in its sector without debt. And in October the company announced a preliminary prospectus with the securities regulatory authorities in Canada, excepting the Quebec province, for a proposed initial public offering of common shares and listing on the Toronto Stock Exchange that makes HempFusion the first US-based cannabidiol (“CBD”) company to apply to list on the TSX (https://ibn.fm/FuBS6). HempFusion Wellness has invested heavily in regulatory compliance in order to meet and exceed the safety and quality standards established not only by government officials, but selective consumers and retailers as well. As a member of the U.S. Hemp Roundtable, the company works with other coalition members in advancing the safety of hemp and CBD products. The company’s focus on regulatory compliance has in turn opened doors to major food and drug mass market retailers. HempFusion has its eye on five channels — natural health retail outlets, Internet-based commerce, big box chains and other mass markets, doctor / care provider referrals and convenience stores. HempFusion’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex products present solutions for basic, specific needs such as sleep, energy and stress. Its offerings include tinctures and capsules, as well as FDA listed over-the-counter (“OTC”) products designed to combat pain, eczema, acne and skin aging, and wounds. HempFusion is one of 12 companies working to capture real world evidence from consumers on how they use CBD products and how their bodies react to those products, with a primary focus on whether daily use is safe for the liver in response to questions raised by the U.S. Food and Drug Administration (https://ibn.fm/482lB). “We believe this real world evidence is important to the FDA and could be used to guide policy moving forward,” Patrick McCarthy, the CEO of life sciences researcher ValidCare, which is conducting the scientific study, stated. Licensed hemp farm acreage decreased on a year-over-year basis in 2020 for the first time since the 2014 Farm Bill established a national hemp pilot program, according to industry watchers (https://ibn.fm/IrgQU). The downward movement was driven by regulatory uncertainty and a vast oversupply of hemp last year in the wake of the previous winter’s updating of the 2014 bill to provide broader legalization to hemp as an agricultural commodity. It is important to note, HempFusion is not a cultivator and is instead focused on product R&D, increased distribution and consumer safety. Nevertheless, Brightfield Group has projected the hemp CBD market to reach $22 billion by 2022 (https://ibn.fm/f7eC4). For more information, visit the company’s website at www.HempFusion.com/Corporate-Information. NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/HempFusion

• Knightscope is building a clientele for its robotic security force models, including about dozens of clients from Fortune 1000 companies, to law enforcement agencies, hospitals, casinos, water utilities, malls and manufacturing plants
• The company’s robots use artificial intelligence to navigate indoor and outdoor areas that are Americans with Disabilities Act compliant, and can be monitored with a simple browser and Internet connection
• The robots record data and use recognition features to assess potentially significant elements such as human activities, thermal changes and license plate information
• The privately held company is backed by more than 16,000 investors and four major corporations, and has raised more than $70 million since its founding in 2013
• Knightscope has now secured its first agreement with the federal government for a project at a Texas Veterans Administration hospital, which the company hopes may lead to more federal projects in the future

A series of publicized incidents in which police officers used violence against racial minorities during the past few years, generating controversy because of their tactics, has led to a nationwide debate about the role of law enforcement and the potential need for police reform. The debate has extended beyond the purview of street-patrolling officers in metropolitan areas, as demonstrated by the recent announcement from the University of Oregon that it will convert several vacant armed police officer positions into frontline, unarmed community service officer positions — an effort to develop more confidence in campus security forces while retaining a backup armed police presence for potentially violent circumstances (https://ibn.fm/9I0id). Autonomous Security Robot developer Knightscope is pursuing a distinct strategy for generating confidence in protective forces. The company’s roving, artificial intelligence-equipped sentries are designed to create a qualified security presence not unlike the one used at the university, presenting a non-threatening patrol that is nonetheless a capable, critical frontline deployment in combating criminal forces. Knightscope’s indoor and outdoor-capable models feature 360-degree eye-level HD streaming video, speakers for recorded or live communication, and recognition features that detect people, faces, license plates, thermal fluctuations and automatic signals. A whimsical CG-animated video of the robots arriving at a train station celebrates the company’s first deployment on behalf of the federal government with an agreement to use them at the Audie L. Murphy Memorial Veteran’s Hospital in San Antonio, Texas (https://ibn.fm/Y7PiG). Knightscope is hopeful its performance there will lead to additional government projects in the future. “One of the more obvious roles for robots in security is that they’re highly productive in repetitive and dangerous tasks,” Stacy Stephens, the vice president of marketing and sales, said in another video that explains how the robots work (https://ibn.fm/KeRYE). “So if you can imagine putting a human being into a place where they’re doing the same thing over and over and over again, they become ineffective very, very quickly. You can also imagine having to put somebody in the line of fire in a dangerous situation — a robot doesn’t care about that. You put them in there instead of a human being, you make it safer and much more productive.” Human operators can then monitor and review the data the sentries collect at will. The robots function in Americans with Disabilities Act-compliant areas, using LiDAR for navigation in combination with sonar and GPS to navigate. They also retain video data for two weeks, which is accessible with a simple Chrome browser and Internet connection. Their mere presence may serve as a deterrent for problems. The company estimates that the robots operate in a price range of about $4 to $11 an hour, which makes their service less expensive than their human counterparts after they’ve been purchased. Clients include about Fortune 1000 clients, such as Samsung and Citizens Bank, five major hospitals plus law enforcement agencies. Using equity crowdfunding, Knightscope has raised millions of dollars to support its operations from a larger pool than most big money companies might seek and is now raising growth capital to scale up its operations. “A lot of larger institutional investors will say, … ‘You have 7,000 investors, they must be driving you mad,’” CEO William Santana Li said during an interview earlier this year with StartEngine strategic adviser Kevin O’Leary, aka Mr. Wonderful (https://ibn.fm/iYrcV). “I tell them, ‘Listen, chief security officers of major corporations are investors of ours. NYPD detectives, FBI, CIA, DHS, vice presidents of leasing of major malls. I would never dare trade out our 7,000 investors for three or four guys (it’s mostly guys) sitting around a table asking the wrong questions, worried about all the wrong things.” Knightscope is now backed by more than 16,000 investors and four major corporations, having raised more than $70 million since it began in 2013. For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/Invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• CEO expects results that will “build the stock and raise the stock price”
• POAI focused on positioning TumorGenesis kits to manufacturers
• Helomics has largest database of its kind in the world, brings cutting-edge technology to cancer research

During a recent NetworkNewsWire exclusive audio interview, Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz noted recent company milestones and outlined strategic goals. In addition, Schwartz provided key updates on the company’s four impressive subsidiaries: Skyline Medical, TumorGenesis, Soluble Biotech and Helomics. “I’m very encouraged. I think we’re moving right along. Things never go as fast as we would like them, and it can be very frustrating at times,” Schwartz stated. “We have a lot going on, and we’re working hard on our goals. . . . We expect results that will be advantageous to the company and that will build the stock and raise the stock price.” During the interview, Schwartz noted that the original purpose of TumorGenesis was to develop a lab media to replace rats and mice in scientific industries as well as the testing of tumors. The company has succeeded in developing the first media: ovarian cancer. “This media, which, as I said, replicates the body, fools the tumor into thinking it’s still in the body,” Schwartz explained. “Its reactions are very, very similar to what it would have done had it been in the body. Now the next step is to get it positioned to manufacturers and getting the kits out so people can use it. That’s coming along handsomely.” Schwartz also talked about POAI’s newest subsidiary, Soluble Biotech, which is essentially the combination of two labs. “We moved them now into a research park,” he said. “We quadrupled the space that they have, and they have the latest in equipment. The technology used by Soluble is proprietary. These machines that we have were developed some time ago and are the only machines of their kind. In the determination of solubility of products, they work wonders in that area. We expect, going forward, that they’ll get a number of contracts.” Finally, Schwartz noted that POAI has positioned Helomics to compete in the marketplace. “The original basis of Helomics . . . was that physicians or hospitals would send their tumors to this company, and they would test the tumors with the known therapies of the day,” he said. “In that process, [Helomics] accumulated over 150,000 tumors covering over 137 different cancer.” Schwartz noted that Helomics currently has the largest database of its kind in the world, and through its subsidiary, POAI brings cutting-edge technology to cancer research and works with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how specific tumors may respond. “With that data, and the fact that we’ve sequenced these tumors, we have shown that we can provide quality information to anyone who needs it,” he continued. “There’s a lot going on at Helomics. We think we’ve validated the company. We’ve got assets that are one-of-a-kind in the world, and we think we are on our way to where we wanted to be when we first purchased this company a couple of years ago.” Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit the company’s website at www.Predictive-Oncology.com NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Subsidiary InsuraGuest Insurance Agency, LLC, is now licensed to offer surplus lines of casualty and property insurance in the state of Utah
• This licensing allows for more markets and additional products to be sold, which generates additional revenue and caters to InsuraGuest’s expansion goals in the insurance marketplace
• Company now offers its products and services throughout the United States in their entirety
• Surplus lines insurance market is expected to reach $125.9 billion by 2027

InsuraGuest Technologies (TSX.V: ISGI) (OTC: IGSTF), a leader in the insurtech industry, now offers its insurance services and products nationwide and has gained access to more markets and revenue streams after being approved as a resident surplus lines producer, receiving a license to offer surplus lines casualty and surplus lines property insurance in the state of Utah. In a November 5, 2020 press release announcing the pivotal moment, InsuraGuest said the license was granted to its wholly owned subsidiary InsuraGuest Insurance Agency, LLC (IG Agency). As a result, IG Agency can now sell other non-admitted insurance products, as well as be listed as official producer for InsuraGuest’s Hospitality Liability Master Policy on all certificates issued to hotels and vacation rentals (https://ibn.fm/eAXw5). Surplus lines insurance protects against a financial risk that is too high for a regular insurance company to take on. Reasons that a company may require surplus lines insurance include:

• Poor loss history
• Business operations are unusual, hazardous, or difficult to assess the true risk – environmental cleanup, wind farms, amusement parks
• The necessity for coverages not offered by standard insurers
• Beginning a new venture or starting a higher risk business
• The necessity for higher limits or broader coverage than insurers are willing to provide

The insurance market changes rapidly, which pushes standard insurers to reassess risk and liability. They may suddenly refuse to insure the same types of risks they did weeks ago. That is where surplus lines insurance steps in to protect those needing insured (https://ibn.fm/bTPni). The market size for surplus lines insurance in the US was valued at $52.1 billion in 2019. By 2027, it is expected to reach $125.9 billion growing at a CAGR of 15.2% from 2020 to 2027. While already covering nontraditional needs, surplus lines insurance can also provide coverage for other industry sectors such as healthcare, construction, environmental, energy, and many other non-conventional services (https://ibn.fm/q9eWg). The licensing will allow InsuraGuest to capitalize on this insurance sector while also opening up more market opportunities to sell additional products and create more revenue streams. “We are very excited to now offer our products and services throughout the United States in their entirety,” said InsuraGuest CEO and Chairman Douglas Anderson. “We continue to expand and develop our product offerings to service our customers and build shareholder value, and the ability to provide true nationwide coverage marks a proud milestone for InsuraGuest.” InsuraGuest’s main goal is to disrupt the insurance landscape by utilizing its proprietary insurtech software platform to deliver digital insurance to multiple sectors. The company aims to transform the way insurance is delivered with the revolutionary idea that insurance should be bought, not sold. One of the sectors InsuraGuest is serving is the hospitality industry, where its proprietary insurtech platform integrates with approximately 70 different property management systems. The company’s Hospitality Liability Policy was designed to fill the gaps in other policies on the market, including a claims process that is easier to navigate. In addition, properties covered by the Hospitality Liability Policy can transfer certain liabilities to the InsuraGuest carrier, thus lowering their claim ratio and risk profile, as well as their general liability premiums. For more information, visit the company’s website at www.InsuraGuest.com. NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Survey suggest over 60% of millennials willing to accept lower returns if an investment is sustainable, 83% considering transitioning entire pension into sustainable portfolio
• SGTM produces environmentally beneficial products using natural waste created by hurricanes and storms while preventing burdens on municipal landfills
• SGTM recorded 794% increase in revenue and 4,817% increase in gross profit compared to all of 2019, preparing for future uplisting

Discretionary spending across almost all sectors has taken a dive in recent months as the global recession deepens. Despite the negative performance across many consumer goods and service sectors, some businesses continue to survive – and even thrive. Among them is Sustainable Green Team (OTC: SGTM), a leading provider of solutions for tree and storm waste disposal that turns problems into profits through the transformation of natural waste into products that benefit the environment. Awareness around sustainable investing appears to be increasing, particularly among millennials who appear to be driving the movement. A recent survey suggests that over 60% of investors within this age group would accept lower returns if an investment is ethical while 83% are considering transitioning their entire pension into a sustainable portfolio (https://ibn.fm/zDXtA). “You do not have to sacrifice returns when investing in a socially responsible portfolio,” said Jamie Broderick, Impact Investing Institute & former UK CEO of UBS Wealth Management. “There are several different categories along the spectrum of capital, and you can choose how you’d like to invest in line with your values, whether in line with market returns, or on a concessionary basis.” SGTM provides an opportunity for investors to take part in a sustainable business with significant growth potential. Through its subsidiaries, the company provides tree services that include debris hauling, debris removal, biomass recycling, mulch and playground surface material manufacturing, product packaging and sales. Founded in sustainability and based on vertically integrated operations, the company takes its role as a steward of the environment seriously by diverting this natural material from landfills and transforming it into a variety of organic, attractive, next-generation products that benefit the natural landscape. SGTM’s expansion plans include organic growth strategies, national partnerships and strategic acquisitions. Following a busy storm season that included Hurricane Laura relief efforts, the company was awarded a string of contracts with large companies that included The Kroger Co., Circle K, 7-Eleven, Old Castle Lawn & Garden, Menards Inc., and many more. The company has commenced the FORM-10 process to become fully reporting and, in anticipation of a future uplisting, disclosing a massive 794% increase in revenue and a 4,817% gross profit increase in the first half of 2020 when compared to all months in 2019 combined (https://ibn.fm/eL8dv). Along with its stellar financial results, SGTM’s impressive overall performance is a testament to the expertise of its management, bolstered by over 40 years of next-level experience across all the company’s verticals. It may not make front page news or create a buzz like electric vehicles or biotech innovation, but the work carried out by SGTM makes a positive impact that directly improve the lives of citizens in the communities the company serves – all while sharing the profits with its loyal group of investors. To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/l1Pgk. NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM